title: [Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
abstract: Three strains of human esophageal carcinoma xenografts established in our institution were tested against combination chemotherapy in vivo and in vitro. TS-1 plus cisplatin (CDDP) was shown to be an effective combination against two carcinoma strains of moderately-differentiated type. Determination of the thymidylate synthase (TS) demonstrated a higher inhibition of the enzyme by adding CDDP to 5-FU, suggesting biochemical modulation. The remaining strain of poorly-differentiated type was resistant to the combination and an attempt was made to add docetaxel (DTX) to show that the three-drug combination was effective against the strain. Combination chemotherapy including TS-1 and CDDP thus appears to be useful treatment choice for esophageal carcinoma.
authors.affiliation: Biomedical Laboratory, Kitasato Institute Hospital.
authors.forename: Takaya
authors.initials: T
authors.lastname: Yamada
authors.forename: Asako
authors.initials: A
authors.lastname: Masuda
authors.forename: Miki
authors.initials: M
authors.lastname: Tongu
authors.forename: Osamu
authors.initials: O
authors.lastname: Hiraku
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Etou
authors.forename: Ken
authors.initials: K
authors.lastname: Sasaki
authors.forename: Koichiro
authors.initials: K
authors.lastname: Atsuda
authors.forename: Seijiro
authors.initials: S
authors.lastname: Morinaga
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Suzuki
authors.forename: Yukio
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Osaku
authors.forename: Takeshi
authors.initials: T
authors.lastname: Miyagawa
authors.forename: Fumiki
authors.initials: F
authors.lastname: Asanuma
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Yamada
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D000077143:Docetaxel; D004338:Drug Combinations; D004357:Drug Synergism; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010094:Oxonic Acid / Q000008:administration & dosage / Q000494:pharmacology; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology; D013385:Succinate Dehydrogenase / Q000037:antagonists & inhibitors; D043823:Taxoids / Q000008:administration & dosage / Q000494:pharmacology; D005641:Tegafur / Q000008:administration & dosage / Q000494:pharmacology; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D004338:Drug Combinations; D011725:Pyridines; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D013385:Succinate Dehydrogenase; D013940:Thymidylate Synthase; D002945:Cisplatin; D005472:Fluorouracil